GeneDx Holdings Corp. $WGS Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Key Points

• Sumitomo Mitsui Trust Group increased its stake in GeneDx by 30.6% in Q4, acquiring 89,470 shares to hold 381,725 shares (about a 1.32% stake) valued at roughly $49.65 million.
• Insiders have been net sellers, disposing of 112,808 shares worth about $8.25 million over the past three months — including CEO Katherine Stueland (46,933 shares) and CFO Kevin Feeley (5,706 shares) — with insiders still owning 29.6% of the company.
• Operational and market snapshot: GeneDx beat Q4 EPS estimates ($0.14 vs. $0.11) on $120.99 million revenue, has a market cap near $1.98 billion, and carries a consensus analyst rating of "Moderate Buy" with a target around $140.71.

Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) by 30.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 381,725 shares of the company's stock after acquiring an additional 89,470 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 1.32% of GeneDx worth $49,647,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp grew its holdings in GeneDx by 664.3% during the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company's stock worth $25,000 after acquiring an additional 186 shares during the period. Quarry LP grew its holdings in GeneDx by 248.8% during the third quarter. Quarry LP now owns 293 shares of the company's stock worth $32,000 after acquiring an additional 209 shares during the period. Gordian Capital Singapore Pte Ltd acquired a new position in GeneDx during the third quarter worth $65,000. AlphaQuest LLC grew its holdings in GeneDx by 70.8% during the third quarter. AlphaQuest LLC now owns 1,303 shares of the company's stock worth $140,000 after acquiring an additional 540 shares during the period. Finally, Spire Wealth Management acquired a new position in GeneDx during the fourth quarter worth $221,000. Institutional investors and hedge funds own 61.72% of the company's stock.

GeneDx Stock Up 0.9%

WGS opened at $67.46 on Thursday. The business's fifty day moving average is $76.63 and its two-hundred day moving average is $111.27. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. The company has a market cap of $1.98 billion, a price-to-earnings ratio of -89.95 and a beta of 2.17. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $170.87.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The company had revenue of $120.99 million for the quarter, compared to the consensus estimate of $120.80 million. Analysts anticipate that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Kevin Feeley sold 5,706 shares of the company's stock in a transaction on Monday, March 16th. The stock was sold at an average price of $76.80, for a total value of $438,220.80. Following the sale, the chief financial officer directly owned 27,148 shares in the company, valued at $2,084,966.40. This represents a 17.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Katherine Stueland sold 46,933 shares of the company's stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $63.17, for a total value of $2,964,757.61. Following the completion of the sale, the chief executive officer owned 91,514 shares in the company, valued at $5,780,939.38. This represents a 33.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 112,808 shares of company stock valued at $8,245,748 over the last three months. Insiders own 29.60% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on WGS shares. Canaccord Genuity Group upped their price objective on GeneDx from $160.00 to $170.00 and gave the stock a "buy" rating in a report on Monday, December 22nd. Piper Sandler reaffirmed an "overweight" rating and set a $130.00 price objective (down from $160.00) on shares of GeneDx in a report on Tuesday, February 24th. BTIG Research decreased their target price on GeneDx from $200.00 to $170.00 and set a "buy" rating on the stock in a research report on Tuesday, February 24th. Wells Fargo & Company upgraded GeneDx from an "equal weight" rating to an "overweight" rating and set a $155.00 target price on the stock in a research report on Monday, February 9th. Finally, Wall Street Zen downgraded GeneDx from a "buy" rating to a "hold" rating in a research report on Sunday, February 8th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, GeneDx currently has a consensus rating of "Moderate Buy" and a consensus target price of $140.71.

GeneDx Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

Want to see what other hedge funds are holding WGS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GeneDx Holdings Corp. (NASDAQ:WGS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.